Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study from researchers at Oxford University’s Departments of Zoology and Biochemistry shows that warring bacteria will engage in suicidal attacks in vast numbers to take down competitors.

© Elisa Granato
Illustration shows magenta cells bursting open, committing suicide and releasing toxins to kill the competitor and save their clonemates

Bacteria are aggressive organisms that have evolved a host of draconian ways to kill and inhibit their competitors. One of the most extreme of these strategies is where cells actively break themselves apart and die to release large toxins that kill other strains. While it was known that some bacteria do this, the extent of the behaviour was not known and it was typically assumed that only a few cells would perform these suicidal attacks.

A new study, published today in Current Biology, shows this is far from the case: in some areas of bacterial battlegrounds, almost all cells will kill themselves to generate a massive simultaneous attack.

Suicidal behaviours are very rare in the natural world and it is typically hard to understand why they would evolve. This study reveals that millions of bacteria will simultaneously engage in a suicidal behaviour. Moreover, it shows that this occurs in the best studied of all bacteria: the common gut bacterium, Escherichia coli. This discovery has striking similarities to behaviours seen in social insects, bee and ant

Read more on the University of Oxford website

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.